RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.63
+5.52%Year over year
Reported trailing growth
- Revenue
- -14.9%
- EBITDA
- +23.8%
- EBIT
- +16.3%
- EPS
- +41.6%
- Free cash flow
- +10.1%
- Operating cash flow
- +8.5%
Forward estimates
Based on analyst estimates
- Revenue
- +4.4%
- EBITDA
- +8.4%
- EPS
- +14.2%
Three-year CAGR
- Revenue
- +23.5%
- EBITDA
- -31.1%
- EBIT
- -35.3%
- Net income
- -39.1%
- EPS
- +14.8%
- Free cash flow
- -1.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026